Table 3

Meta-analysis of HIV incidence for high-risk population using PrEP versus that not using PrEP

MTC categoriesUsing PrEP groupNot using PrEP groupPooled incidence RR (95% CI)
Estimates(n)PYs followed* Pooled incidence per 100 PYs (95% CI)I2 (%)PYs followedPooled incidence per 100 PYs (95% CI)I2 (%)
Total1324 7201.27 (0.68 to 2.36)96.3017 2103.08 (2.15 to 4.40)92.700.45 (0.31 to 0.67)
Good (≥80%)354350.60 (0.42 to 0.84)0.0054382.83 (1.59 to 4.99)88.900.28 (0.19 to 0.41)
Moderate (60%~80%)399590.65 (0.35 to 1.21)80.1061971.61 (0.59 to 4.35)94.100.42 (0.29 to 0.62)
Poor (<60%)588432.80 (1.31 to 5.90)96.7051114.15 (3.39 to 5.07)52.700.75 (0.45 to 1.25)
  • *Because one study might have different study drug type (eg, TDF and/or TDF/FTC), there were 13 independent PrEP efficacy estimates and 11 estimates for both MTC and protective efficacy in the 10 included studies.

  • MTC, medicine-taking compliance; PrEP, pre-exposure prophylaxis; PYs, person years; RR, risk ratio; FTC, emtricitabine; TDF, tenofovir disoproxil fumarate.